Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes
|ClinicalTrials.gov Identifier: NCT00433641|
Recruitment Status : Completed
First Posted : February 12, 2007
Last Update Posted : March 14, 2011
Control of food intake, size and frequency of meals are critical to the development of obesity. The stomach signals feelings of fullness after a meal and therefore plays a role in control of calorie intake. It is unclear whether the approved appetite reducing drug sibutramine changes the function of the stomach. Differences in the way individuals respond to treatment with the appetite suppressant sibutramine may also explain why some people lose weight while others do not.
In a previous study of 48 overweight or obese participants, we preliminarily observed that variation in the gene for the promoter of the serotonin transporter protein was significantly associated with degree of weight loss.
This new single center clinical study aims to evaluate the effects of the FDA-approved appetite suppressing medication, sibutramine (MERIDIA)on weight loss and stomach emptying in patients who are overweight or obese. The effect of individual differences in inherited genes that modify serrotonin and noradrenergic receptors on weight reduction with sibutramine will be tested.
|Condition or disease||Intervention/treatment||Phase|
|Obesity||Drug: sibutramine||Phase 4|
Background:. Genetic variations are potentially key to inter-individual differences in responses to treatment with the appetite suppressant sibutramine.
Overall Aims: To evaluate influence of genetic variation in candidate adrenergic and serotonergic control mechanisms on weight loss and gastric emptying response to sibutramine in obesity.
Methods: 180 overweight or obese (respectively BMI of 25-29.9 or 30 kg/m2) people treated with sibutramine (10 or 15 mg/day) or placebo for 12 wks. We shall collect DNA from venous blood sample at study entry, and use SERT-P genotype at baseline to stratify patients according to LL vs LS/SS genotype in both obese and overweight groups. The primary outcome measurement will be the association of clinical response (weight loss) and the influence of SERT-P and 2-MSP variation. A secondary outcome for descriptive purposes is the gastric emptying response to sibutramine treatment. Gastric emptying of solids will be measured using stable isotope method.
Anticipated Results: SERT-P genotype is significantly associated with the magnitude of weight loss in obese and overweight individuals.
Significance: Our study will provide the first evidence of the pharmacogenomic effects of sibutramine on weight loss in obesity and appraise the association of weight loss with change in gastric emptying.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||181 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Pharmacogenomics of Weight Loss With Sibutramine in Obese and Overweight Patients|
|Study Start Date :||July 2006|
|Primary Completion Date :||November 2007|
|Study Completion Date :||November 2007|
Placebo Comparator: 1
Other Name: meridia
oral sibutramine 10 mg once per day
Other Name: MERIDIA
oral 15 mg sibutramine once per day
Other Name: MERIDIA
- Association of weight loss with candidate genotypes [ Time Frame: 2006-2007 ]
- T1/2 gastric emptying of solids [ Time Frame: 2006-2007 ]
- body composition (fat) [ Time Frame: 2006-2007 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00433641
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Michael L. Camilleri, M.D.||Mayo Clinic|